The global psoriatic arthritis treatment market is witnessing strong momentum as the rising prevalence of psoriasis and psoriatic arthritis continues to increase the demand for advanced treatment options. Ongoing innovations in biologics, targeted therapies, and oral medications, coupled with expanding healthcare infrastructure and increasing investments in pharmaceutical research, are creating a favorable environment for sustained market growth.
The growing focus on early diagnosis, personalized treatment approaches, and improved patient outcomes is encouraging pharmaceutical companies to strengthen their product portfolios through continuous research and development. As healthcare providers increasingly adopt advanced therapies to prevent disease progression and improve quality of life, the market is expected to experience significant expansion over the coming years.
Market Size (2025): USD 12.9 Billion
Market Size (2026): USD 14.6 Billion
CAGR (Forecast Period): 13.1%
Forecast Year: 2034
Projected Market Size (2034): USD 39.08 Billion
Dominant Region: North America
Fastest Growing Region: Asia-Pacific
Market Overview
Psoriatic arthritis is a chronic autoimmune inflammatory disease that affects joints, tendons, ligaments, and skin, commonly developing in patients with psoriasis. Without timely treatment, the condition can lead to irreversible joint damage and reduced mobility. Modern treatment strategies focus on controlling inflammation, minimizing skin symptoms, relieving pain, and preventing long-term disability.
Growing awareness regarding autoimmune diseases, expanding access to specialty care, and continuous advancements in biologics and disease-modifying therapies are reshaping treatment standards worldwide. Increasing healthcare spending and favorable regulatory support for innovative therapies are further strengthening the outlook for the global market.
Growth Drivers
The increasing prevalence of psoriasis and psoriatic arthritis remains one of the strongest growth drivers for the market. Millions of people worldwide are affected by psoriasis, with a significant proportion eventually developing psoriatic arthritis, creating consistent demand for effective long-term therapies.
Another major factor supporting market growth is the expanding clinical pipeline. Pharmaceutical companies continue to invest heavily in research focused on next-generation biologics, TYK2 inhibitors, and other targeted therapies designed to improve efficacy while reducing side effects. The growing number of late-stage clinical candidates is expected to introduce additional treatment options over the forecast period.
Furthermore, improvements in diagnostic capabilities, greater physician awareness, and broader patient access to specialty medications continue to accelerate treatment adoption across developed and emerging healthcare markets.
Market Challenges
Despite strong growth prospects, several challenges continue to limit market expansion. High treatment costs, particularly for biologics and specialty medicines, remain a significant barrier in many low- and middle-income countries.
Limited healthcare infrastructure, shortages of trained specialists, and restricted reimbursement policies in developing regions also reduce patient access to advanced therapies. In addition, delayed diagnosis and lower awareness of psoriatic arthritis continue to affect treatment rates in underserved populations.
Emerging Opportunities
Emerging economies are expected to create substantial opportunities for market participants throughout the forecast period. Countries across Asia-Pacific are investing significantly in healthcare infrastructure while expanding pharmaceutical manufacturing capabilities and improving patient access to advanced treatments.
Growing domestic pharmaceutical industries, increasing healthcare expenditure, rising insurance coverage, and stronger government support for chronic disease management are expected to accelerate market penetration. Continued investment in biosimilars and innovative targeted therapies is also likely to enhance treatment affordability and expand the patient base.
Segment Analysis
The biologics segment continues to lead the market due to its superior effectiveness in managing moderate to severe psoriatic arthritis. These therapies selectively target immune pathways responsible for inflammation, helping reduce disease activity while slowing joint damage progression.
Based on treatment type, prescription medications account for the largest market share as biologics and disease-modifying antirheumatic drugs (DMARDs) remain the preferred treatment options for patients requiring long-term disease management.
By route of administration, injectable therapies dominate the market owing to their rapid therapeutic response, proven clinical effectiveness, and widespread use of biologic medicines. Increasing patient acceptance of self-injectable devices and improvements in drug delivery technologies continue to strengthen this segment.
Regional Analysis
North America remains the largest contributor to the global psoriatic arthritis treatment market. The region benefits from advanced healthcare systems, strong pharmaceutical research capabilities, favorable reimbursement structures, and the presence of several leading biopharmaceutical companies. High disease awareness, continuous innovation, and widespread adoption of biologic therapies further support regional market leadership.
Asia-Pacific is projected to record the fastest growth throughout the forecast period. Rising healthcare investments, expanding pharmaceutical manufacturing, increasing awareness of autoimmune disorders, and improving access to advanced therapies are creating significant opportunities across countries including China and India. Continued healthcare reforms and growing research activities are expected to further accelerate regional expansion.
Europe continues to represent a mature and steadily growing market supported by robust healthcare infrastructure, strong clinical research activity, and increasing use of biologic therapies. Meanwhile, Latin America, the Middle East, and Africa are gradually emerging as attractive markets as healthcare systems continue to improve and access to advanced treatments expands.
Competitive Landscape
Leading market participants are focusing on product innovation, strategic collaborations, clinical research, and geographic expansion to strengthen their competitive positions. Continuous investments in biologics, biosimilars, and next-generation targeted therapies are expected to shape future market competition.
Key Companies
AbbVie Inc.
Amgen Inc.
Bausch Health Companies Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Eli Lilly and Company
Johnson & Johnson Services, Inc.
Novartis International AG
Pfizer Inc.
UCB S.A.
Recent Developments
In November 2023, Takeda announced encouraging Phase 2b clinical trial results for TAK-279, an investigational oral allosteric TYK2 inhibitor developed for patients with active psoriatic arthritis, highlighting continued progress in targeted oral therapies.
During the same month, Amgen reported positive findings from its global Phase 4 FOREMOST study evaluating Otezla® (apremilast) in patients with early oligoarticular psoriatic arthritis, reinforcing the company's commitment to expanding treatment options for earlier stages of the disease.
Click to Read the Complete Insights & Report: https://straitsresearch.com/report/psoriatic-arthritis-treatment-market
Future Outlook
The global psoriatic arthritis treatment market is expected to maintain strong growth through 2034, supported by increasing disease prevalence, expanding biologics adoption, and continuous pharmaceutical innovation. Advances in targeted therapies, growing investment in clinical research, and broader access to modern treatment options across emerging markets are expected to reshape disease management and improve long-term patient outcomes. As healthcare systems increasingly prioritize early intervention and personalized medicine, the market is well positioned for sustained expansion over the coming decade.
About Straits Research
Straits Research is a global market intelligence and consulting company that delivers actionable research, analytics, and advisory services across diverse industries. The company provides comprehensive market reports, customized research solutions, competitive intelligence, and strategic insights that help organizations identify growth opportunities, evaluate market trends, and make informed business decisions in an evolving global marketplace.
Top comments (0)